Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Total Liabilities
Everything the company owes to creditors and other parties.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 38.6% from a year ago
Total liabilities stood at $1.75B at the end of Q3 FY2026, up 38.6% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.
Context
- Total liabilities amounted to 31.1% of total assets at the end of Q3 FY2026, up 1.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +38.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.38B USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- +18.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.38B | +22.1% |
| FY2024 | 2024-12-31 | 1.13B | +10.8% |
| FY2023 | 2023-12-31 | 1.02B | +54.2% |
| FY2022 | 2022-12-31 | 660.9M | -5.4% |
| FY2021 | 2021-12-31 | 698.5M | — |
Total Liabilities vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's Sep 2026 total liabilities of $1.75B is the 2nd highest of the 10 companies compared; the peer median is $358.52M.
- Its year-over-year change of +38.6% is the 3rd highest of 10, against a peer median of +19.7%.
- Total liabilities amounts to 31.1% of total assets for NBIX, versus a peer median of 35.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $7.81B | +5.5% | -1.8% | 65.1% | |
| Sep 2026 | $1.75B | +38.6% | +27.8% | 31.1% | |
| Jun 2026 | $678.14M | +19.7% | +39.4% | 89.1% | |
| Sep 2026 | $406.66M | -1.7% | +21.6% | 22.7% | |
| Jun 2026 | $396.88M | +24.6% | -21.8% | 27.8% | |
| Jun 2026 | $358.52M | -13.8% | +48.1% | 96.7% | |
| Mar 2026 | $152.76M | +26.8% | +14.8% | 35.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M | +193.1% | -53.6% | 54.1% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Mar 2026 | $11.89M | +16.1% | +23.3% | 4.3% | |
| Peer median (excluding NBIX) | $358.52M | +19.7% | +21.6% | 35.2% | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 340.8M | 262.9M | 251.1M | 233M | 713M |
| Short-term Investments | 370.5M | 726.4M | 780.5M | 843.1M | 767.4M |
| Net Receivables | 185.5M | 350M | 439.3M | 479.1M | 686.8M |
| Inventory | 30.5M | 35.1M | 38.3M | 57.4M | 69M |
| Other Current Assets | 45.5M | 79.1M | 97.8M | 63.6M | 115.8M |
| Total Current Assets | 972.8M | 1.45B | 1.61B | 1.72B | 2.52B |
| Property, Plant & Equipment (Net) | 155.8M | 145.6M | 347.3M | 592M | 545.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 37.2M | 35.5M | 36.5M | 0 |
| Long-term Investments | 624.4M | 401.5M | 849.4M | 864.3M | 1.18B |
| Tax Assets | 315.1M | 305.9M | 362.6M | 485.7M | 320.3M |
| Other Non-current Assets | 4.4M | 25M | 49.6M | 15.5M | 59.5M |
| Total Non-current Assets | 1.1B | 915.2M | 1.64B | 1.99B | 2.11B |
| Total Assets | 2.07B | 2.37B | 3.25B | 3.72B | 4.63B |
| Account Payables | 51.5M | 67.3M | 133.3M | 99.9M | 104.9M |
| Short-term Debt | 0 | 169.4M | 170.1M | 0 | 0 |
| Tax Payables | 0 | 9M | 24.4M | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 133.3M | 225.4M | 261.4M | 297.8M | 423.9M |
| Total Current Liabilities | 245.8M | 537.7M | 654.8M | 507.7M | 743.4M |
| Long-term Debt | 335.1M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 12.3M | 29.7M | 106.3M | 166.2M | 219.7M |
| Total Non-current Liabilities | 452.7M | 123.2M | 364.6M | 621.3M | 635M |
| Total Liabilities | 698.5M | 660.9M | 1.02B | 1.13B | 1.38B |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | (635.8M) | (406.8M) | (157.1M) | 29.2M | 447.7M |
| Accumulated OCI | (1.7M) | (7.9M) | 7M | 5.8M | 13.1M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B |
| Total Debt | 440.4M | 262.9M | 428.4M | 455.1M | 415.3M |
| Net Debt | 99.6M | 0 | 177.3M | 222.1M | (297.7M) |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.